^
Association details:
| Biomarker: | H3F3A mutation + ARID2 mutation |
|---|---|
| Cancer: | Giant Cell Tumor of Bone |
| Drug: | Prolia (denosumab) (RANK ligand inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation
Published date:
03/11/2021
Excerpt:
We report on three patients with H3F3A-mutated GCTBs, treated with denosumab...A biopsy was performed and the diagnosis of GCTB was confirmed by detection of the H3F3A G34W mutation...a mutation of ARID2 in the recurrence of the GCTB under treatment with denosumab.
DOI:
10.1038/s41598-021-85319-x.
